Welcome to LookChem.com Sign In|Join Free

CAS

  • or

870837-19-7

Post Buying Request

870837-19-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

870837-19-7 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 870837-19-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,0,8,3 and 7 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 870837-19:
(8*8)+(7*7)+(6*0)+(5*8)+(4*3)+(3*7)+(2*1)+(1*9)=197
197 % 10 = 7
So 870837-19-7 is a valid CAS Registry Number.

870837-19-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-methoxy-4-(5-methyl-1H-imidazol-1-yl)benzaldehyde

1.2 Other means of identification

Product number -
Other names 3-methoxy-4-(5-methylimidazol-1-yl)benzaldehyde

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:870837-19-7 SDS

870837-19-7Downstream Products

870837-19-7Relevant articles and documents

SALTS OF CYNNAMIDE COMPOUND OR SOLVATES THEREOF

-

Page/Page column 14, (2008/12/07)

The invention provides crystals of dihydrochloride monohydrate of the compound of the following formula having an Aβ production inhibiting effect which crystals are characterized by exhibiting a diffraction peak at an angle of diffraction (2θ ± 0.2°) of 10.9° in powder X-ray diffractometry. Further, the invention also provides the compound in the form of various salts, crystal forms and amorphous forms which are suitable for the development of drugs.

Therapeutic agent for Abeta related disorders

-

Page/Page column 29, (2010/11/24)

The present invention provides a pharmaceutical composition comprising at least one member selected from a compound capable of enhancing Aβ37 production, a compound capable of inhibiting Aβ40 and Aβ42 production and enhancing Aβ37 production, and salts of

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 870837-19-7